Recursion Pharmaceuticals reports GAAP EPS of -$0.22
Recursion Pharmaceuticals reported a GAAP EPS of -$0.22, beating estimates by $0.04. The company’s revenue was $6.47M.
The revenue figure missed estimates by $9.31M. The company’s financial performance is being closely watched by investors.
The earnings report provides insight into the company’s financial health. The difference between actual and estimated revenue is significant, with a shortfall of $9.31M from the expected $6.47M + $9.31M = $15.78M, but the EPS beat expectations.